Crispr Therapeutics AG (CRSP) Expected to Post Earnings of -$0.74 Per Share

Analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will announce earnings of ($0.74) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is ($0.77) and the highest is ($0.71). Crispr Therapeutics reported earnings per share of ($0.40) during the same quarter last year, which indicates a negative year over year growth rate of 85%. The company is expected to report its next quarterly earnings results on Friday, March 9th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.49) to ($2.43). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.06) per share, with EPS estimates ranging from ($3.08) to ($3.04). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. During the same quarter in the previous year, the business posted ($2.77) earnings per share. The company’s revenue was up 54.2% compared to the same quarter last year.

Several brokerages have recently issued reports on CRSP. Oppenheimer began coverage on Crispr Therapeutics in a report on Thursday, December 7th. They set a “hold” rating for the company. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Piper Jaffray Companies reiterated a “buy” rating and set a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday. SunTrust Banks reiterated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. Finally, Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.81.

Shares of Crispr Therapeutics (NASDAQ:CRSP) opened at $28.52 on Friday. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $30.79. The company has a market capitalization of $1,170.00 and a PE ratio of -89.13.

In related news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $18.98, for a total value of $21,114,225.08. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kurt Von Emster sold 37,754 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $26.76, for a total value of $1,010,297.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,168,504 shares of company stock valued at $42,538,573. 39.98% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of CRSP. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Vanguard Group Inc. bought a new position in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $273,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new position in Crispr Therapeutics in the 3rd quarter worth approximately $235,000. Finally, Hershey Trust Co. bought a new position in Crispr Therapeutics in the 3rd quarter worth approximately $768,000. 24.52% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Crispr Therapeutics AG (CRSP) Expected to Post Earnings of -$0.74 Per Share” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2018/01/13/crispr-therapeutics-ag-crsp-expected-to-post-earnings-of-0-74-per-share.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply